IP Library Patent Application 14725298
Patent Application
App. No. 14/725,298

SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/725,298
Abstract

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Claims (34)

1 . A compound of Formula I, including pharmaceutically acceptable salts thereof,

wherein:

Q is:

R 1 is hydrogen;

R 2 is hydrogen, halogen, or methoxy;

R 3 is hydrogen;

R 4 is a heteroaryl group, wherein said heteroaryl group is optionally substituted with one to three different substituents selected from group F;

wherein - - represents a carbon-carbon bond or does not exist;

R 5 is hydrogen;

R 6 does not exist;

m is 2;

—W— is

R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl;

A is phenyl, furan or pyridine;

F is selected from the group consisting of —(C 1-6 )alkyl, hydroxy, —(C 1-6 )alkoxy, —C(O)R 57 , —NR 42 C(O)—(C 1-6 )alkyl, —NR 42 S(O) 2 —(C 1-6 )alkyl, —NR 42 R 43 , and —COOR 54 ;

R 42 and R 43 are independently selected from hydrogen and (C 1-6 )alkyl;

R 54 is selected from the group consisting of hydrogen and (C 1-6 )alkyl; and

R 57 is selected from the group consisting of hydrogen and (C 1-6 )alkyl.

2 . The compound of claim 1 , wherein said heteroaryl group is selected from the group consisting of thiazole, pyridazine, pyrazole, imidazole, furyl, thienyl, oxazole, oxadiazole, pyrimidine, pyrazole, tetrazole and pyridyl.

3 . A compound of Formula I, including pharmaceutically acceptable salts thereof,

wherein:

Q is:

R 1 is hydrogen;

R 2 is hydrogen, halogen, or methoxy;

R 3 is hydrogen;

R 4 is a heteroaryl group, wherein said heteroaryl group is selected from the group consisting of:

wherein X 2 represents the point of attachment;

wherein - - represents a carbon-carbon bond or does not exist;

R 5 is hydrogen;

R 6 does not exist;

m is 2;

—W— is

A is phenyl, furan or pyridine; and

R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , are each independently selected from the group consisting of hydrogen and (C 1-6 )alkyl.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 039324 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 8, 2016
From: BRISTOL-MYERS SQUIBB COMPANY
To: VIIV HEALTHCARE UK (NO. 4) LIMITED
Reel/Frame 039945/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: BRISTOL-MYERS SQUIBB COMPANY
To: VIIV HEALTHCARE (NO. 4) LIMITED
Reel/Frame 039324/0016 →